The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Sep. 20, 5:59 PM

Slide #6. Oncothyreon Inc. Secondary Offering

Company: Oncothyreon Inc. (NASDAQ:ONTY)
Date announced: 9/17/2014
Shares Offered: 10,000
Secondary Offering Details: Oncothyreon Inc. (NASDAQ: ONTY) today announced that it intends to offer and sell shares of its Common Stock and Series A Convertible Preferred Stock in separate but concurrent underwritten public offerings. The Series A Convertible Preferred Stock is non-voting and convertible into shares of Oncothyreon Common Stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would beneficially own more than 4.99% of the Common Stock then outstanding. As part of the Common Stock offering, Oncothyreon also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. The offerings are being conducted as separate public offerings by means of separate prospectus supplements, and neither offering is contingent upon the consummation of the other. The offerings are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings.

Oncothyreon is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. Co.'s primary product candidate under clinical development is Tecemotide, which is designed to induce an immune response to destroy cancer cells that express Mucin 1 (MUC1), a protein antigen expressed on many common cancers. Co. has also developed a synthetic MUC1-based liposomal glycolipopeptide cancer vaccine, ONT-10, for potential use in several cancer indications. Co. is developing ONT-380 as part of a collaboration with Array BioPharma Inc., primarily for the treatment of metastatic breast cancer, including patients with brain metastases.
Open the ONTY Page at The Online Investor »

Company Name:  Oncothyreon Inc
Website:  www.oncothyreon.com
Sector:  Biotechnology
Number of ETFs Holding ONTY:  11
Total Market Value Held by ETFs:  $3.65M
Total Market Capitalization:  $142.00M
% of Market Cap. Held by ETFs:  2.57%
 

Open the ONTY Page at The Online Investor (in a new window) »

September 20, 2014    5:59 PM Eastern
Quotes delayed 20 minutes



Buy (3.00 out of 4)
48th percentile
(ranked lower than approx. 52% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.